The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor on Noise- Induced Hearing Loss

Author

Department of Audiology, Faculty of Rehabilitation, Rehabilitation Research Center, Iran University of Medical Sciences, Tehran, Iran

Abstract

Objective(s): Noise-induced hearing loss (NIHL) is the major cause of acquired hearing loss.  Celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, is a non- steroidal anti- inflammatory drug (NSAID) with known antioxidant and antineoplastic activity. Therefore, we monitored the extent of temporary noise- induced threshold shifts (TTS) and cochlear damage caused by high level 4- kHz noise exposure to verify the differences with those pretreated with celecoxib.
Materials and Methods: Ten male albino guinea pigs (300-350 g in weight) were randomly allocated into two groups: the primal group was exposed to 4- kHz octave band noise at 102 dB SPL for 3 hrs (group 1, n=5);  the latter pretreated with 50 mg/ kg celecoxib for 3 days, then  exposed to noise (group 2, n=5).  Before exposure and one hr after noise exposure, threshold shifts were evaluated with auditory brainstem responses (ABR) and finally the animals were euthanized for histological evaluation. 
Results: Comparing the threshold shifts before/after noise exposure with those pretreated, we found out that TTS caused by noise exposure did not show significant mitigation by celecoxib.  By observing the organ of Corti at lower middle turn of cochlea in celecoxib pretreated group, considerable hair cell loss was discovered.
Conclusion:The current study clearly confirmed that celecoxib had no attenuation against temporary noise-induced hearing loss.

Keywords

References

  1. Yamane H, Nakai Y, Takayama M, Iguchi H, Nakagawa T, Kojima A. Appearance of free radicals in the guinea pig inner ear after noise-induced acoustic trauma. Eur Arch Otorhinolaryngol 1995; 252:504- 508.
  2. Ohlemiller KK, Wright JS, Dugan LL. Early elevation of cochlear reactive oxygen species following noise exposure. Audiol Neurootol 1999; 4:229- 236.
  3. Shi X, Ren T, Nuttall AL. The electrochemical and fluorescence detection of nitric oxide in the cochlea and its increase following loud sound. Hear Res 2002; 164:49- 58.
  4. Arteel GE, Briviba K, Sies H. Protection against peroxynitrite. FEBS Lett  1999; 44:226- 230.
  5. Li MH, Jang JH, Surh YJ. Nitric oxide induces apoptosis via AP-1-driven upregulation of COX-2 in rat pheochromocytoma cells. Free Radic Biol Med 2005; 39:890- 899.
  6. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K, et al. A single amino acid differences between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivirty of COX-2 specific inhibitors. J Biol Chem 1996; 271:15810-15814.
  7. Barnett J, Chow J, Ives D, Chiou M, Mackenzie R, Osen E, et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculivirus system. Biochem Biophys Acta  1994; 1209:130- 139.
  8. Ziegler EA, Brieger J, Heinrich UR, Mann WJ, Chambers HF, Sande MA, et al. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG. editors. Goodman and Gilman’s, The Pharmacological Basis of Therapeutics. McGraw–Hill, New York: 1996.p. 1103–1121.
  9. Hoshino T, Tabuchi K, Hirose Y, Uemaetomari I, Murashita H, Tobita T, et al. The non- steroidal anti- inflammatpry drugs protects mouse cochlea against acoustic injury. Tohoku J Exp Med  2008; 216:53- 59.
  10. 10.  Matsuda K, Nakamura S, Matsushita T. Celecoxib inhibits nitric oxide production in chondrocytes of ligament-damaged osteoarthritic rat joints. Rheumatol Int 2006; 26:1- 5.
  11. 11.  Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H. In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci 2005; 35:137- 143.
  12. 12.  Penning TD, Talky JJ, Bertenshaw JR. Synthesis and biological evaluation of the 1,5-dioxy pyrazol class of cyclooxygenase inhibitors: Identification of 4-[5-1,4-methyl phenyl 3-trifluromethyl-III-pyrazole-1-yl] benzene sulfonimide (SC-56635 celecoxib). J Med Chem 1997; 40:1347– 1365.
  13. 13.  Simon LS, Laza FL, Lipsky PE. Preliminary study of the safety and efficacy of sc 56635, a novel cyclooxygenase 2 inhibitor. Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum 1998; 41:1591–1502.
  14. 14.  Jendrossek V. Targeting apoptosis pathways by celecoxib in cancer. Cancer Lett 2011; In press.
  15. 15.  Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban- Wilhelm H, Angioni C, et al.  The anti- proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008; 76:179- 187.
  16. 16.  Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et- al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355:885- 895.
  17. 17.  Niederberger E, Tegeder I, Vetter G, Schmidtko A, Schmidt H, Euchenhoffer C, et al.  Celecoxib loses its anti- inflammatory efficacy at high doses through activation of NF- kB. FASEB J 2001; 15:1622- 1626.
  18. 18.  Pourbakht A, Yamasoba T, Cochlear damage caused

by continuos and intermittent noise exposure. Hear Res 2003; 178:70-78.

19. Raphael Y. Altschuler RA. Scar formation after drug-induced cochlear insult. Hear Res 1991; 51:173-184.

  1. 20.  Harding G W, Bohne BA. Relation of focal hair-cell lesions to noise-exposure parameters from a 4- or a 0.5-kHz octave band of noise. Hear Res 2009; 254:54- 63.  
  2. 21.  Yamasoba T, Nuttall AL, Harris C, Raphael Y, Miller JM. Role of glutathione in protection against noise-induced hearing loss. Brain Res 2008; 784:82-90.
  3. 22.  Kopke RD, Weisskopf PA, Boone JL, Jackson RL, Wester DL, Hoffer ME, et al.  Reduction of noise- induced hearing loss using L- Nac and salicylates in the chinchilla. Hear Res 2000; 149:138- 146.
  4. 23.  Pourbakht A, Yamasoba T. Ebselen attenuates cochlear damage caused by acoustic trauma. Hear Res 2003;181:100- 108.
  5. 24.  Ajith TA, Sanjay PS, Babitha NV. Antimutagenic and anti-oxidant activities of the non-steroidal anti-inflammatory drug celecoxib. Clin Exp Pharmacol Physiol 2000; 32: 888– 893.
  6. 25.  Rhee CK, Park YS, Jung TTK, Park CI. Effects of leukotriens and prostaglandins on cochlear blood flow in the chinchilla. Eur Arch Otorhinolaryngol 1999; 256:479- 483.
  7. 26.  Miller JM, Brown JN, Schacht J. 8- Iso- prostaglandin F2 alfa, a product of noise exposure, reduces inner ear blood flow. Audiol Neurootol 2003; 8:207- 221.
  8. 27.  Lamm  K, Arnold W. The effect of prednisolone and non- steroidal anti- inflammatory agents on the normal and noise- damaged guinea pig inner ear. Hear Res 1998; 115:149- 161.
  9. 28.  Sha SH, Taylor R, Forge A, Schacht J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear Res 1999: 155:1- 8.
  10. 29.  Dai CF, Steygerm PS. A systemic gentamycin pathway across the stria vascularis . Hear Res 2008; 235:114- 124.

 

 

 

 

 

 

 

 

Files

Share

How to cite

Statistics